Startup Behind AstraZeneca Covid 19 Vaccine Plans To File Publicly For U.S. IPO Within Days

(Reuters) - Vaccitech Plc, the biotech startup that owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca Plc, priced its ordinary shares at $17 each on Thursday ahead of its U.S. initial public offering.

Source : https://www.usnews.com/news/technology/articles/2021-04-29/vaccitech-prices-shares-at-17-for-us-ipo

Vaccitech Prices Shares at $17 for U.S. IPO
AstraZeneca finally reaches vaccine shipping milestone to EU that was due in January
COVID-19 news today: Ontario to receive new AstraZeneca shipment next week, will reserve doses for second shots
Vaccitech, startup behind Oxford COVID-19 vaccine tech, falls 20% in Nasdaq debut
The Latest: EU plans Pfizer vaccine contract extension
So you received the AstraZeneca COVID-19 vaccine — now what?
Factbox-Some countries limit AstraZeneca vaccine use, U.S. pauses J&J shot
One AZ COVID-19 vaccine dose gives 80% lower death risk – English data
Vaccitech, startup behind Oxford COVID-19 vaccine tech, falls 20% in Nasdaq debut